Alaunos Therapeutics Inc (STU:WEK)
€ 1.66 0 (-4.82%) Market Cap: 338.23 Mil Enterprise Value: 276.94 Mil PE Ratio: 0 PB Ratio: 1.04 GF Score: 54/100

ZIOPHARM Oncology Inc at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 08:15PM GMT
Release Date Price: €4.1 (-1.44%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Welcome to the Morgan Stanley Healthcare Conference. And before I get going, I'm going to give the requisite disclosures. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk.

I'm one of the biotech analysts here. My name is David Lebowitz, and I'd like to -- I'm happy to welcome with me on the stage from ZIOPHARM, CEO, Dr. Laurence Cooper.

Laurence James Neil Cooper
ZIOPHARM Oncology, Inc. - CEO & Director

Thank you so much.

Questions & Answers

David Neil Lebowitz
Morgan Stanley, Research Division - VP

And I guess kind of a new company here in a way. If you could -- Ziopharm is a developer of immunotherapy for treatment -- immunotherapies for the treatment of cancer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot